🏛️ Verified NIH Record • Updated 2025-08-19
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (NCT03470922)
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0010 — Tucson, Arizona
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (127 Sites)
Showing the first 25 of 127 sites.
- Local Institution - 0010 — Tucson, Arizona
- Local Institution - 0020 — Los Angeles, California
- Coastal Integrative Cancer Care — San Luis Obispo, California
- Local Institution - 0116 — Santa Barbara, California
- Local Institution - 0012 — Washington D.C., District of Columbia
- Local Institution - 0013 — Jacksonville, Florida
- Local Institution - 0117 — Orlando, Florida
- Local Institution - 0007 — Tampa, Florida
- Local Institution - 0038 — Atlanta, Georgia
- Local Institution - 0016 — Chicago, Illinois
- Local Institution - 0114 — Fort Wayne, Indiana
- Local Institution - 0077 — Baltimore, Maryland
- Local Institution - 0120 — Baltimore, Maryland
- Local Institution - 0014 — Boston, Massachusetts
- Local Institution - 0134 — Boston, Massachusetts
- Local Institution - 0015 — Ann Arbor, Michigan
- Local Institution - 0009 — Minneapolis, Minnesota
- Local Institution - 0011 — Rochester, Minnesota
- Local Institution - 0018 — Charlotte, North Carolina
- Local Institution - 0019 — Allentown, Pennsylvania
- Local Institution - 0076 — Dallas, Texas
- Local Institution - 0008 — Houston, Texas
- Local Institution - 0135 — Buenos Aires, Distrito Federal
- Local Institution - 0002 — Capital Federal, Distrito Federal
- Local Institution - 0004 — Buenos Aires,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.